期刊
JOURNAL OF IMMUNOLOGY
卷 177, 期 6, 页码 3930-3938出版社
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.177.6.3930
关键词
-
类别
资金
- NCI NIH HHS [R01 CA048115] Funding Source: Medline
In an effective immune response, CD8(+) T cell recognition of virally derived Ag, bound to MHC class 1, results in killing of infected cells. The CD8 alpha beta heterodimer acts as a coreceptor with the TCR, to enhance sensitivity of the T cells to peptide/MHC class 1, and is two orders of magnitude more efficient as a coreceptor than the CD8 alpha alpha. To understand the important interaction between CD8 alpha beta and MHC class 1, we created a panel of CD8 beta mutants and identified mutations in the CDRI, CDR2, and CDR3 loops that decreased binding to MHC class I tetramers as well as mutations that enhanced binding. We tested the coreceptor function of a subset of reducing and enhancing mutants using a T cell hybridoma and found similar reducing and enhancing effects. CD8 beta-enhancing mutants could be useful for immunotherapy by transduction into T cells to enhance T cell responses against weak Ags such as those expressed by tumors. We also addressed the question of the orientation of CD8 alpha beta with MHC class I using CD8 alpha mutants expressed as a heterodimer with wild-type CD8 alpha or CD8 beta. The partial rescuing of binding with wild-type CD8 beta compared with wild-type CD8 alpha is consistent with models in which either the topology of CD8aa and CD8 alpha beta binding to MHC class I is different or CD8 alpha beta is capable of binding in both the T cell membrane proximal and distal positions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据